Faculty profile

Kuo-Shyan Lin

ResearcherMolecular OncologyUniversity of British Columbia

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of British Columbia directory, so their courses and email address may be missing. Find their university profile.

Kuo-Shyan Lin

Researcher

Molecular Oncology

Health Sciences

University of British Columbia

Vancouver, British Columbia, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
38 publications in the last five years, latest in 2026.
Senior (last) author on 22 recent papers, a sign of leading a research group.
Principal investigator on 5 research grants (5 CIHR), most recently in 2022.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

113

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Cancer Imaging Radiopharmaceuticals Positron Emission Tomography Targeted Radioligand Therapy Prostate-Specific Membrane Antigen Gastrin-Releasing Peptide Receptor Bradykinin B1 Receptor Albumin Binder

Latest papers

PSMA binding of carbamate-containing peptidomimetics influenced by side chain length and stereocenter configuration in preclinical prostate cancer model.
Bioorganic & medicinal chemistry · 2026
Unnatural Amino Acid Substitutions to Improve In Vivo GRPR-Targeting Capability of [68Ga]Ga-SP01011 for Cancer Imaging.
Molecular pharmaceutics · 2026 · senior author
A simple solid-phase approach for the synthesis of DOTA-conjugated α-ketoamide-based fibroblast activation protein-targeted ligands.
Bioorganic & medicinal chemistry letters · 2026 · senior author

All 113 publications

Latest funding

Next-generation GRPR-targeting radiopharmaceuticals with improved in vivo stability and minimized pancreas uptake
CIHR · 2022 · Nominated PI
$523,260
Development of second-generation radiopharmaceuticals targeting the C-X-C chemokine receptor 4 for imaging and therapy of hematological cancers
CIHR · 2022 · Co-investigator
$860,626
Simultaneously targeting cancer cells and tumor stroma to improve detection sensitivity and therapeutic efficacy of radiopharmaceuticals
CIHR · 2021 · Nominated PI
$772,650

All 14 grants and awards

113 publications.

PSMA binding of carbamate-containing peptidomimetics influenced by side chain length and stereocenter configuration in preclinical prostate cancer model.

Roxin Á, Merkens H, Zhang C, Colpo N, Zhang Z, Tan R, Lin KS, Bénard F

Bioorganic & medicinal chemistry2026

DOI: 10.1016/j.bmc.2026.118779 PMID: 42623854

Unnatural Amino Acid Substitutions to Improve In Vivo GRPR-Targeting Capability of [68Ga]Ga-SP01011 for Cancer Imaging.

Pathania S, Chen CC, Ng P, Merkens H, Lau WS, Lau J, Bénard F, Lin KS

Molecular pharmaceutics2026Senior author

DOI: 10.1021/acs.molpharmaceut.6c00854 PMID: 42704131

A simple solid-phase approach for the synthesis of DOTA-conjugated α-ketoamide-based fibroblast activation protein-targeted ligands.

Jozi S, Ng P, Merkens H, Cookson F, Bénard F, Lin KS

Bioorganic & medicinal chemistry letters2026Senior author

DOI: 10.1016/j.bmcl.2026.130693 PMID: 42176782

Synthesis and evaluation of [68Ga]Ga-DOTA-Pip-PEP-4 derivatives for imaging gastrin-releasing peptide receptor expression with positron emission tomography.

Pathania S, Jozi S, Chen CC, Ng P, Lau WS, Merkens H, Lau J, Bénard F, Lin KS

Nuclear medicine and biology2026Senior author

DOI: 10.1016/j.nucmedbio.2026.109674 PMID: 42603345

Synthesis and Evaluation of 68Ga-Labeled NT(6-13) Analogs Incorporating Non-Canonical Amino Acid Substitutions at Tyr11 for Targeting NTSR1 in Various Solid Malignancies.

Kaur S, Mair S, Lau WS, Zeisler J, Bénard F, Lin KS, Lau J

ACS omega2026

DOI: 10.1021/acsomega.6c02356 PMID: 42206223

First-in-Human Evaluation of [68Ga]Ga-HTK03149, a PSMA-Targeted Tracer for PET Imaging in Prostate Cancer.

Chaussé G, Hou X, Uribe C, Harsini S, Pan J, Saprunoff H, Allan H, Kuo HT, Lin KS, Wilson D, Bénard F

Journal of nuclear medicine : official publication, Society of Nuclear Medicine2026

DOI: 10.2967/jnumed.123.266357 PMID: 41748290

Development of an Optimized CXCR4-Targeting Theranostic Pair.

Kwon D, Bloise I, Zhang Z, Colpo N, Wilson R, Tan R, Merkens H, Zeisler J, Lau J, Lin KS, Bénard F

Journal of nuclear medicine : official publication, Society of Nuclear Medicine2026

DOI: 10.2967/jnumed.125.269933 PMID: 41611474

Synthesis and Evaluation of Novel 68Ga-Labeled GRPR-Targeted PET Tracers Derived from [d-Phe6,Pro14]Bombesin(6-14) and [d-Phe6,des-Met14]Bombesin(6-14) Sequences.

Jozi S, Pathania S, Wang L, Chen CC, Lau WS, Ng P, Merkens H, Bénard F, Lin KS

Molecular pharmaceutics2026Senior author

DOI: 10.1021/acs.molpharmaceut.5c01683 PMID: 41607011

Is Thiourea the Weak Link? An Investigation of the In Vitro and In Vivo Destabilization of [203Pb]- and [212Pb]Pb2+ Thiourea-Based Bioconjugates.

McNeil BL, Wharton L, Chen CC, Merkens H, Čolović M, Rodríguez-Rodríguez C, Wilson J, Mair S, Zhang C, McDonagh AW, Lin KS, Bénard F, Wuest F, Schaffer P, Ramogida CF

ACS bio & med chem Au2026

DOI: 10.1021/acsbiomedchemau.5c00224 PMID: 41726328

Synthesis and Preclinical Evaluation of Dual-Mode Fluorescent 18F-PET Tracers Targeting PSMA.

Lozada J, Merkens H, Froelich J, Tai RA, Lin KS, Bénard F, Perrin DM

Journal of medicinal chemistry2025

DOI: 10.1021/acs.jmedchem.5c01480 PMID: 40737542

Something wrong or missing on this profile? Suggest a correction

Kuo-Shyan Lin

Research

Latest papers

Latest funding

PSMA binding of carbamate-containing peptidomimetics influenced by side chain length and stereocenter configuration in preclinical prostate cancer model.

Unnatural Amino Acid Substitutions to Improve In Vivo GRPR-Targeting Capability of [68Ga]Ga-SP01011 for Cancer Imaging.

A simple solid-phase approach for the synthesis of DOTA-conjugated α-ketoamide-based fibroblast activation protein-targeted ligands.

Synthesis and evaluation of [68Ga]Ga-DOTA-Pip-PEP-4 derivatives for imaging gastrin-releasing peptide receptor expression with positron emission tomography.

Synthesis and Evaluation of 68Ga-Labeled NT(6-13) Analogs Incorporating Non-Canonical Amino Acid Substitutions at Tyr11 for Targeting NTSR1 in Various Solid Malignancies.

First-in-Human Evaluation of [68Ga]Ga-HTK03149, a PSMA-Targeted Tracer for PET Imaging in Prostate Cancer.

Development of an Optimized CXCR4-Targeting Theranostic Pair.

Synthesis and Evaluation of Novel 68Ga-Labeled GRPR-Targeted PET Tracers Derived from [d-Phe6,Pro14]Bombesin(6-14) and [d-Phe6,des-Met14]Bombesin(6-14) Sequences.

Is Thiourea the Weak Link? An Investigation of the In Vitro and In Vivo Destabilization of [203Pb]- and [212Pb]Pb2+ Thiourea-Based Bioconjugates.

Synthesis and Preclinical Evaluation of Dual-Mode Fluorescent 18F-PET Tracers Targeting PSMA.

Next-generation GRPR-targeting radiopharmaceuticals with improved in vivo stability and minimized pancreas uptake

Development of second-generation radiopharmaceuticals targeting the C-X-C chemokine receptor 4 for imaging and therapy of hematological cancers

Simultaneously targeting cancer cells and tumor stroma to improve detection sensitivity and therapeutic efficacy of radiopharmaceuticals

PSMA/CAIX-targeting radioligands to improve the management of clear cell renal cell carcinoma

Dual Isotope Theranostics for 18F-PET Imaging and Correlated Targeted Radioligand Therapy

Cleavable linkers to reduce kidney uptake of peptide radiopharmaceuticals

Dual-Mode PET imaging agents for PET imaging cancer and visualizing tumor margins

Targeted radiopharmaceuticals to improve cancer diagnosis and treatment

Advancing the clinical development of [18F]AMBF3-TATE, a novel imaging probe for neuroendocrine tumours

18F-Labeled Arylboronate-Peptides for Cancer Imaging

Frequent collaborators

Paul Schaffer

Valery Radchenko

Francois Benard

Carlos Uribe

Hua Yang

Shoukat Dedhar

David Perrin

Frank Wuest

Samuel Aparicio

Christian Steidl

Kuo-Shyan Lin

Research

Latest papers

Latest funding

PSMA binding of carbamate-containing peptidomimetics influenced by side chain length and stereocenter configuration in preclinical prostate cancer model.

Unnatural Amino Acid Substitutions to Improve In Vivo GRPR-Targeting Capability of [68Ga]Ga-SP01011 for Cancer Imaging.

A simple solid-phase approach for the synthesis of DOTA-conjugated &#x3b1;-ketoamide-based fibroblast activation protein-targeted ligands.

Synthesis and evaluation of [68Ga]Ga-DOTA-Pip-PEP-4 derivatives for imaging gastrin-releasing peptide receptor expression with positron emission tomography.

Synthesis and Evaluation of 68Ga-Labeled NT(6-13) Analogs Incorporating Non-Canonical Amino Acid Substitutions at Tyr11 for Targeting NTSR1 in Various Solid Malignancies.

First-in-Human Evaluation of [68Ga]Ga-HTK03149, a PSMA-Targeted Tracer for PET Imaging in Prostate Cancer.

Development of an Optimized CXCR4-Targeting Theranostic Pair.

Synthesis and Evaluation of Novel 68Ga-Labeled GRPR-Targeted PET Tracers Derived from [d-Phe6,Pro14]Bombesin(6-14) and [d-Phe6,des-Met14]Bombesin(6-14) Sequences.

Is Thiourea the Weak Link? An Investigation of the In Vitro and In Vivo Destabilization of [203Pb]- and [212Pb]Pb2+ Thiourea-Based Bioconjugates.

Synthesis and Preclinical Evaluation of Dual-Mode Fluorescent 18F-PET Tracers Targeting PSMA.

Frequent collaborators

Paul Schaffer

Valery Radchenko

Francois Benard

Carlos Uribe

Hua Yang

Shoukat Dedhar

David Perrin

Frank Wuest

Samuel Aparicio

Christian Steidl

A simple solid-phase approach for the synthesis of DOTA-conjugated α-ketoamide-based fibroblast activation protein-targeted ligands.